James Woodruff Emlen

Connetics Corp. develops and commercializes dermatology products. The firm offers remedies for psoriasis in adults, eczema, seborrheic dermatitis, and acne. The company was founded in 1993 and is headquartered in Palo Alto, CA.

InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA.

Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen's targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts.

MenoGenix, Inc. operates as a biotechnology company. It focuses on development of drugs for menopause and the menopause diseases. The company was founded by Debra M. Duke and Jonathan Kaufman in 2010 and is headquartered in Aurora, CO.